Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Control Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

NCT03290248
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen, Healthy Volunteers
Interventions
B244 suspension, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

NCT03660878
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 2 Interventional

Tocotrienol Against the Progression of End Stage Liver Disease

NCT02581085
View directory record Official record
Conditions
End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
Tocotrienol (TCT), Placebo
Drug · Other
Lead sponsor
Chandan Sen
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 3:16 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

NCT07548632
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab
Other · Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
14
States / cities
Aliso Viejo, California • Garden Grove, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

NCT02952898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • San Ramon, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 2 Interventional

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

NCT01060878
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PYM50028, Placebo
Drug
Lead sponsor
Phytopharm
Industry
Eligibility
35 Years to 75 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Results available

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

NCT00770133
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen/naphazoline, Naphazoline, Ketotifen, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
INO-8875, Placebo
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 77 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

NCT00713609
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl peroxide gel, Clindamycin gel, Tazarotene cream, Vehicle gel, Vehicle cream
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Little Rock, Arkansas • Fremont, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 1 Interventional

A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.

NCT07795567
View directory record Official record
Conditions
Rosacea
Interventions
Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 20, 2026, 3:16 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

NCT01797107
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Azasite
Drug
Lead sponsor
Philadelphia Eye Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation

NCT01430533
View directory record Official record
Conditions
Healthy
Interventions
azelaic acid pre foam formulation, Vehicle pre foam formulation, Water
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 20, 2026, 3:16 AM EDT
Recruiting Phase 2 Interventional

Topical Ketotifen 0.25% for Secondary Vestibulodynia

NCT07257029
View directory record Official record
Conditions
Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia, Vulvary Pain Disorders, Neuroproliferative Vestibulodynia, Mast Cell-mediated Neuroinflammation, Instertional Dyspareunia
Interventions
Ketotifen Fumarate 0.25% Cream, Placebo (Vehicle Cream)
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951
View directory record Official record
Conditions
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
3 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Bel Air, Maryland • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements

NCT03760042
View directory record Official record
Conditions
Healthy
Interventions
Within-Subject Active vs. Placebo Topical Applications
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

NCT02045277
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion, IDP-118 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
18
States / cities
Encino, California • San Diego, California • Santa Rosa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

NCT01551056
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss

NCT04450602
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 20, 2026, 3:16 AM EDT
Completed No phase listed Observational

The New England Bladder Cancer Study

NCT00342875
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years to 79 Years
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Characterization of Nicotine Exposure and Urge-to-Smoke Following Use of Electronic and Conventional Cigarettes

NCT02210754
View directory record Official record
Conditions
Smoking
Interventions
blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle), blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle), Marlboro Cigarette
Other
Lead sponsor
Lorillard Tobacco Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

NCT03019627
View directory record Official record
Conditions
Dry Eye
Interventions
NGF, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Controlled Trial to Improve Teen Driving

NCT01624597
View directory record Official record
Conditions
Motor Vehicle Driving
Interventions
In-vehicle video feedback, Parent communication
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
14 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
2
States / cities
Des Moines, Iowa • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04201574
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ALY688 0.1%, ALY688 0.4%, Vehicle
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 20, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

NCT02336503
View directory record Official record
Conditions
Hyperhidrosis
Interventions
BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%, Vehicle
Drug
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
12
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 20, 2026, 3:16 AM EDT